drugset / Trial / NCT01339572
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Non-randomizedParallel-groupOpen-labelSupportive care
Summary
This protocol will investigate the effectiveness of plerixafor in the up-front setting in avoiding a second round of mobilization and whether this translates into a clinical and economic benefit.
Timeline
- Start
- 2011-04
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plerixafor | Small molecule | 240 ug/kg | — |
| Background | filgrastim | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |
| Background | filgrastim | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |